Literature DB >> 17450338

Usefulness of FDG PET for diagnosis and radiotherapy of the patient with malignant lymphoma involving bone marrow.

Takashi Nihashi1, Kazumasa Hayasaka, Toshihide Itou, Takashi Sobajima, Rikio Kato, Kengo Ito, Yoshiyuki Ito, Takeo Ishigaki, Shinji Naganawa.   

Abstract

We experienced a case of relapsed malignant lymphoma with multiple bone marrow or bone lesions. The case was diagnosed as follicular lymphoma by cytological biopsy of the right iliac bone, with (67)Ga scintigraphy showing abnormal, intense uptake in multiple bones. After about 10 months of systemic chemotherapy, a relapse was suspected because of pain in the bilateral legs and a high level of lactate dehydrogenase. Assessment of the lesions in the patient was difficult by computed tomography because the affected sites were localized mainly in the bone marrow. (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) was useful for detecting accurately the relapse sites in the bone marrow and enabled us to determine the field for radiotherapy. There are only a few reports of FDG-PET findings for such bone marrow malignant lymphomas. Therefore, we report the findings of FDG-PET for this case and review some of the literature about bone marrow lymphomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17450338     DOI: 10.1007/s11604-006-0110-6

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  13 in total

1.  PET-CT of extranodal lymphoma.

Authors:  Ur Metser; Odelia Goor; Hedva Lerman; Elizabeth Naparstek; Einat Even-Sapir
Journal:  AJR Am J Roentgenol       Date:  2004-06       Impact factor: 3.959

2.  18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum.

Authors:  Martha Hoffmann; Andreas Chott; Andreas Püspök; Ulrich Jäger; Kurt Kletter; Markus Raderer
Journal:  Ann Hematol       Date:  2003-12-12       Impact factor: 3.673

3.  Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone.

Authors:  Y H Park; S Kim; S-J Choi; B-Y Ryoo; S H Yang; G J Cheon; C-W Choi; S M Lim; J Y Yoo; S-S Lee
Journal:  Ann Oncol       Date:  2005-05-03       Impact factor: 32.976

Review 4.  Staging and classification of lymphoma.

Authors:  Ping Lu
Journal:  Semin Nucl Med       Date:  2005-07       Impact factor: 4.446

5.  Extranodal malignant lymphoma: detection with FDG PET versus CT.

Authors:  F Moog; M Bangerter; C G Diederichs; A Guhlmann; E Merkle; N Frickhofen; S N Reske
Journal:  Radiology       Date:  1998-02       Impact factor: 11.105

6.  Usefulness of FDG-PET imaging for the radiotherapy treatment planning of pyothorax-associated lymphoma.

Authors:  Hirofumi Asakura; Taro Togami; Masahiro Mitani; Hitoshi Takashima; Koiku Yokoe; Yuka Yamamoto; Yoshihiro Nishiyama; Toshihide Monden; Yoshihiro Toyama; Motoomi Ohkawa
Journal:  Ann Nucl Med       Date:  2005-12       Impact factor: 2.668

7.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading.

Authors:  S Wöhrer; U Jaeger; K Kletter; A Becherer; A Hauswirth; K Turetschek; M Raderer; M Hoffmann
Journal:  Ann Oncol       Date:  2006-02-23       Impact factor: 32.976

9.  Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy.

Authors:  Elena V Dizendorf; Brigitta G Baumert; Gustav K von Schulthess; Urs M Lütolf; Hans C Steinert
Journal:  J Nucl Med       Date:  2003-01       Impact factor: 10.057

10.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.